Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab + MRG003 versus MRG003 induction before chemoradiotherapy in locally advanced head and neck squamous cell carcinoma
2023-510558-18-00Phase 2Authorised
- Sponsor
- GORTEC
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pucotenlimab and becotatug vedotin in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by GORTEC. Primary endpoint: Best objective response rate. Planned start Oct 2025; status: authorised.
02
Drugs
pucotenlimabbecotatug vedotin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-510558-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510558-18-00.